Natixis upgraded shares of Astrazeneca PLC (NYSE:AZN) from a neutral rating to a buy rating in a report issued on Wednesday, Marketbeat.com reports.
AZN has been the topic of a number of other reports. Leerink Swann restated an outperform rating and issued a $36.00 price target (up from $33.00) on shares of Astrazeneca PLC in a research report on Wednesday, May 17th. Barclays PLC restated an overweight rating on shares of Astrazeneca PLC in a research report on Monday, July 3rd. Zacks Investment Research downgraded shares of Astrazeneca PLC from a strong-buy rating to a sell rating in a research report on Monday, July 17th. BidaskClub downgraded shares of Astrazeneca PLC from a hold rating to a sell rating in a research report on Monday, July 24th. Finally, Goldman Sachs Group, Inc. (The) restated a sell rating on shares of Astrazeneca PLC in a research report on Thursday, July 13th. Four equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and thirteen have issued a buy rating to the company. The stock currently has an average rating of Hold and an average price target of $33.60.
Shares of Astrazeneca PLC (NYSE AZN) opened at 32.25 on Wednesday. The company has a 50-day moving average of $30.20 and a 200-day moving average of $31.61. The stock has a market capitalization of $81.66 billion, a PE ratio of 21.15 and a beta of 0.74. Astrazeneca PLC has a 12 month low of $25.55 and a 12 month high of $35.60. Astrazeneca PLC also was the recipient of some unusual options trading activity on Thursday. Traders bought 21,026 call options on the company. This represents an increase of 777% compared to the typical daily volume of 2,397 call options.
Astrazeneca PLC (NYSE:AZN) last posted its quarterly earnings data on Thursday, July 27th. The company reported $0.87 EPS for the quarter, beating the Zacks’ consensus estimate of $0.41 by $0.46. Astrazeneca PLC had a net margin of 17.80% and a return on equity of 35.90%. The firm had revenue of $5.05 billion for the quarter, compared to the consensus estimate of $5.04 billion. During the same period in the prior year, the firm posted $0.83 EPS. The firm’s revenue was down 9.9% compared to the same quarter last year. On average, equities research analysts expect that Astrazeneca PLC will post $1.85 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Astrazeneca PLC (AZN) Upgraded to Buy at Natixis” was originally reported by Markets Daily and is the sole property of of Markets Daily. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://www.themarketsdaily.com/2017/09/10/astrazeneca-plc-azn-upgraded-to-buy-at-natixis.html.
The business also recently announced a None dividend, which will be paid on Monday, September 11th. Shareholders of record on Friday, August 11th will be paid a dividend of $0.44 per share. The ex-dividend date is Wednesday, August 9th. This represents a yield of 2.98%. Astrazeneca PLC’s payout ratio is 44.92%.
Several institutional investors and hedge funds have recently made changes to their positions in AZN. Meeder Asset Management Inc. acquired a new position in shares of Astrazeneca PLC in the 2nd quarter worth approximately $105,000. Salem Investment Counselors Inc. acquired a new position in shares of Astrazeneca PLC in the 1st quarter worth approximately $107,000. Tower Research Capital LLC TRC grew its stake in shares of Astrazeneca PLC by 3,782.0% in the 1st quarter. Tower Research Capital LLC TRC now owns 3,882 shares of the company’s stock worth $121,000 after purchasing an additional 3,782 shares during the last quarter. WFG Advisors LP grew its stake in shares of Astrazeneca PLC by 36.0% in the 2nd quarter. WFG Advisors LP now owns 3,716 shares of the company’s stock worth $127,000 after purchasing an additional 984 shares during the last quarter. Finally, Parallel Advisors LLC grew its stake in shares of Astrazeneca PLC by 27.1% in the 1st quarter. Parallel Advisors LLC now owns 4,526 shares of the company’s stock worth $138,000 after purchasing an additional 964 shares during the last quarter. 14.18% of the stock is currently owned by institutional investors.
About Astrazeneca PLC
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.